An interventional study of Continuous glucose monitor in CGM, Intensive Care (ICU) and Liver Transplant Surgery, sponsored by Institute for Clinical and Experimental Medicine. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Institute for Clinical and Experimental Medicine · Not applicable, Interventional, and Device feasibility
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Diabetes Mellitus with a site in Czechia — 8 open to participants now, 12 under way, 3 of them phase 3. Diabetes Mellitus · Czechia.
Among the 120 studies in Diabetes Mellitus with a site in Czechia, this one is the 96th largest by planned enrollment of the 108 interventional ones that give a count, is one of 4 that started in 2026, is one of 14 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 120th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.
Browse Diabetes Mellitus studies →8 of the 120 studies in Diabetes Mellitus with a site in Czechia are open now. Recruiting first, the newest first:
Lukas Vanek · Sites in Czechia
Women only
Bonmedix Holding a.s. · Sites in Czechia
Ages 40+
CSL Behring · Sites in Czechia, United States, Argentina and 32 more countries
Ages 18+
Pharming Technologies B.V. · Sites in Czechia, United States, Australia and 8 more countries
Ages 18+
Charles University, Czech Republic · Sites in Czechia
Ages 18+
A study can be open while its sites in Czechia have not opened yet or have stopped. Only those recruiting at a site in Czechia →
Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 24 · Phase 3 65 · Phase 4 7
First in 1994; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is below the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.
Median enrollment 464 across the 108 interventional studies, 640 across the 12 observational. Of the 102 that completed or were terminated, 61 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
100 of 120 have an industry lead sponsor. The 10 most frequent:
Institute for Clinical and Experimental Medicine is the lead sponsor of 61 studies on the registry; 21 are open to participants now.
Institute for Clinical and Experimental Medicine has 3 studies filed under Diabetes Mellitus — fewer than ten, so there is no comparison to draw.
2 of the studies in Diabetes Mellitus with a site in Czechia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT05650229Pharming Technologies B.V.Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 120 studies in Diabetes Mellitus with a site in Czechia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Main objective:
The goal is to to determine the accuracy of Dexcom G7 Continuous glucose monitor system in critically ill patients, undergoing major abdominal surgery and solid organ transplantation, in the intensive care unit.
On admission to the intensive care unit or at the end of surgery, two Dexcom G7 sensors are placed in the infraclavicular position.
Sensor number 1 will be blinded and will only be active when paired with the receiver, without the ability to monitor glucose levels.
Sensor number 2 is used for continuous glucose monitoring and can be used to adjust the insulin dose.
Patients will wear the continuous glucose monitoring sensor for a maximum of 10 days, including the time spent in the intensive care unit and the immediate care unit. The study will not interfere with any usual care clinical workflows.
Calibration is only performed on an unblinded sensor. The reference method for calibration is the glucose from the blood glucose meter.
Calibrate on the first day of monitoring: 4 times a day after approximately 6 hours, or if the blood glucose reading from the blood glucose meter is not within the estimated error range of the continuous glucose monitor (difference greater than 1,5mmol/L).
Calibration on days 2 and 3 of monitoring: once in the morning, or when the meter's glucose reading is not within the estimated error range of the continuous glucose monitoring (difference greater than 1,5mmol/L) On subsequent days when the blood glucose meter reading is not within the estimated error range of continuous glucose monitoring (difference greater than 1,5mmol/L).
Hypothesis:
Further objectives:
To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety.
To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.
Design:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional calibrations performed on CGM device during monitoring period
Device: Continuous glucose monitor
No additional calibrations performed on CGM device during monitoring period
Device: Continuous glucose monitor
Continuous measurement of glucose from subcutaneous tissue
Calculate overall mean absolute relative difference between arms
Analyse the difference in mean absolute relative difference (MARD) of Dexcom G7 continuous glucose monitor between calibrated and uncalibrated sensor, in patients undergoing major abdominal surgery and solid organ transplantation.
Time frame: From enrolment to discharge from ICU care or up-to day 10
Accuracy metrics
To evaluate further aspects regarding the Dexcom G7 continuous glucose monitor system's performance in the intensive care unit (ICU), particularly in terms of sensitivity and specificity to detect hypo- and hyperglycaemic events, data availability, device deficiencies and safety. To identify predictive factors of the accuracy of the Dexcom G7 continuous glucose monitor system in critically ill patients in the ICU.
Time frame: From enrolment to discharge from ICU care or up-to day 10
Started Jan 2026 (actual). Primary completion is estimated for Sep 2026, 8 months after the start.
Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 8 months is below that.
Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute for Clinical and Experimental Medicine